Heterocyclic compound
The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
1. N-((3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl)-7-(4-(1-methyl-1H-1,2,3-triazol-4-yl)benzyl)furo[3,2-b]pyridine-5-carboxamide, or a salt thereof.
2. N-((3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl)-7-(4-(1-methyl-1H-1,2,3-triazol-4-yl)benzyl)-2,3-dihydrofuro[3,2-b]pyridine-5-carboxamide, or a salt thereof.
3. 7 (3 Fluoro-4-((2-methoxyethyl)carbamoyl)benzyl)-N-((3R,4 S)-3-hydroxytetrahydro-2H-pyran-4-yl)-2,3-dihydrofuro[3,2-b]pyridine-5-carboxamide, or a salt thereof.
4. 7 (3 Fluoro-4-((((S)-tetrahydrofuran-2-yl)methyl)carbamoyl)benzyl)-N-((3R,4 S)-3-hydroxytetrahydro-2H-pyran-4-yl)-2,3-dihydrofuro[3,2-b]pyridine-5-carboxamide, or a salt thereof.
5. 7 (3 Fluoro-4-((((S)-tetrahydrofuran-2-yl)methyl)carbamoyl)benzyl)-N-((3R,4 S)-3-hydroxytetrahydro-2H-pyran-4-yl)furo[3,2-b]pyridine-5-carboxamide, or a salt thereof.
6. A pharmaceutical composition comprising the compound according to claim 1 or a salt thereof and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising the compound according to claim 2 or a salt thereof and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising the compound according to claim 3 or a salt thereof and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising the compound according to claim 4 or a salt thereof and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the compound according to claim 5 or a salt thereof and a pharmaceutically acceptable carrier.
11. The pharmaceutical composition according to claim 6 , which is a cholinergic muscarinic M1 receptor positive allosteric modulator.
12. The pharmaceutical composition according to claim 6 , which is a therapeutic agent for constipation.
13. A method of cholinergic muscarinic M1 receptor positive allosteric modulation in a mammal, comprising administering an effective amount of the compound according to claim 1 or a salt thereof to said mammal.
14. A method of cholinergic muscarinic M1 receptor positive allosteric modulation in a mammal, comprising administering an effective amount of the compound according to claim 2 or a salt thereof to said mammal.
15. A method of cholinergic muscarinic M1 receptor positive allosteric modulation in a mammal, comprising administering an effective amount of the compound according to claim 3 or a salt thereof to said mammal.
16. A method of cholinergic muscarinic M1 receptor positive allosteric modulation in a mammal, comprising administering an effective amount of the compound according to claim 4 or a salt thereof to said mammal.
17. A method of cholinergic muscarinic M1 receptor positive allosteric modulation in a mammal, comprising administering an effective amount of the compound according to claim 5 or a salt thereof to said mammal.
18. A method for the treatment of constipation in a mammal, comprising administering an effective amount of the compound according to claim 1 or a salt thereof to the mammal.
19. A method for the treatment of constipation in a mammal, comprising administering an effective amount of the compound according to claim 2 or a salt thereof to the mammal.
20. A method for the treatment of constipation in a mammal, comprising administering an effective amount of the compound according to claim 3 or a salt thereof to the mammal.
21. A method for the treatment of constipation in a mammal, comprising administering an effective amount of the compound according to claim 4 or a salt thereof to the mammal.
22. A method for the treatment of constipation in a mammal, comprising administering an effective amount of the compound according to claim 5 or a salt thereof to the mammal.